HRTIS — Herantis Pharma Oyj Income Statement
0.000.00%
Last trade - 00:00- €28.93m
- €22.48m
Annual income statement for Herantis Pharma Oyj, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | FAS | FAS | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | — | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 7.14 | 8.07 | 12.5 | 7.99 | -0.154 |
| Operating Profit | -7.14 | -8.07 | -12.5 | -7.99 | 0.154 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -8 | -9.15 | -12.8 | -9.32 | 0.28 |
| Net Income After Taxes | -8 | -9.15 | -12.8 | -9.32 | 0.28 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8 | -9.15 | -12.8 | -9.32 | 0.28 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8 | -9.15 | -12.8 | -9.32 | 0.28 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.29 | -0.892 | -0.907 | -0.636 | 0.016 |
| Dividends per Share |